Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 29Recruiting 26Unknown 13Active not recruiting 10Terminated 9Withdrawn 5Not yet recruiting 4No longer available 3Enrolling by invitation 3Available 2Approved for marketing 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 6CNS 5NET 4Dermatologic 2Head & Neck 1Gastrointestinal 1

Conditions

Brain Neoplasms 101Glioblastoma 85Glioma 58Central Nervous System Neoplasms 34Astrocytoma 27Neuroblastoma 26Gliosarcoma 19Breast Neoplasms 19Neoplasms 18Oligodendroglioma 17Recurrence 14Neoplasm Metastasis 13Medulloblastoma 12Ependymoma 11Carcinoma, Non-Small-Cell Lung 11Lymphoma 9Sarcoma 8Osteosarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neuroma, Acoustic 7Meningioma 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lung Neoplasms 7Hodgkin Disease 7Burkitt Lymphoma 7Wilms Tumor 6Sezary Syndrome 6Neuroectodermal Tumors, Primitive 6Mycosis Fungoides 6

Interventions

lutetium Lu 177 dotatate 2vandetanib 13-fluorobenzylguanidine 13-Iodobenzylguanidine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Pheochromocytoma × CNS × Clear all
NCT06233903 2025-01-21

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 2 Withdrawn
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT04276597 2023-03-10

PUTNET

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Withdrawn
CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡